DYN Quote, Financials, Valuation and Earnings

Intellia Therapeutics has a net margin of -- compared to Dyne Therapeutics's net margin of -687.61%. Dyne Therapeutics's return on equity of -- beat Intellia Therapeutics's return on equity of -56.9%.

Dyne Therapeutics has a consensus price target of $39.62, signalling upside risk potential of 321.46%. On the other hand Intellia Therapeutics has an analysts' consensus of $37.11 which suggests that it could grow by 213.7%. Given that Dyne Therapeutics has higher upside potential than Intellia Therapeutics, analysts believe Dyne Therapeutics is more attractive than Intellia Therapeutics.

Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intellia Therapeutics has a beta of 2.211, suggesting its more volatile than the S&P 500 by 121.143%.

Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Intellia Therapeutics pays out -- of its earnings as a dividend.

Dyne Therapeutics quarterly revenues are --, which are smaller than Intellia Therapeutics quarterly revenues of $16.6M. Dyne Therapeutics's net income of -$115.4M is lower than Intellia Therapeutics's net income of -$114.3M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Intellia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 26.18x for Intellia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical has a net margin of -- compared to Dyne Therapeutics's net margin of -108.46%. Dyne Therapeutics's return on equity of -- beat Ultragenyx Pharmaceutical's return on equity of -205.06%.

Dyne Therapeutics has a consensus price target of $39.62, signalling upside risk potential of 321.46%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $87.21 which suggests that it could grow by 218.17%. Given that Dyne Therapeutics has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Dyne Therapeutics is more attractive than Ultragenyx Pharmaceutical.

Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.261, suggesting its less volatile than the S&P 500 by 73.884%.

Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

Dyne Therapeutics quarterly revenues are --, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $139.3M. Dyne Therapeutics's net income of -$115.4M is higher than Ultragenyx Pharmaceutical's net income of -$151.1M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 4.34x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Avidity Biosciences has a net margin of -- compared to Dyne Therapeutics's net margin of -7360.01%. Dyne Therapeutics's return on equity of -- beat Avidity Biosciences's return on equity of -29.26%.

Dyne Therapeutics has a consensus price target of $39.62, signalling upside risk potential of 321.46%. On the other hand Avidity Biosciences has an analysts' consensus of $66.56 which suggests that it could grow by 95.52%. Given that Dyne Therapeutics has higher upside potential than Avidity Biosciences, analysts believe Dyne Therapeutics is more attractive than Avidity Biosciences.

Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Avidity Biosciences has a beta of 0.908, suggesting its less volatile than the S&P 500 by 9.163%.

Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avidity Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Avidity Biosciences pays out -- of its earnings as a dividend.

Dyne Therapeutics quarterly revenues are --, which are smaller than Avidity Biosciences quarterly revenues of $1.6M. Dyne Therapeutics's net income of -$115.4M is higher than Avidity Biosciences's net income of -$115.8M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Avidity Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 465.35x for Avidity Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -- compared to Dyne Therapeutics's net margin of -60.08%. Dyne Therapeutics's return on equity of -- beat Sarepta Therapeutics's return on equity of -20.94%.

Dyne Therapeutics has a consensus price target of $39.62, signalling upside risk potential of 321.46%. On the other hand Sarepta Therapeutics has an analysts' consensus of $44.16 which suggests that it could grow by 101%. Given that Dyne Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Dyne Therapeutics is more attractive than Sarepta Therapeutics.

Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.179%.

Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Dyne Therapeutics quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Dyne Therapeutics's net income of -$115.4M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 1.09x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.